• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Segment 13: Final Thoughts on Clinical Diagnostic Tests

Article

The panelists share their thoughts on the future of diagnostic tests and what changes they are looking forward to, such as developing better systems to integrate clinical information with molecular data and increased FDA oversight.

The panelists share their thoughts on the future of diagnostic tests and what changes they are looking forward to.

Bryan Loy, MD, MBA, is optimistic about the future, but recognizes that the issues of accountability and FDA governance are the least of the concerns in the area of diagnostic testing.

Daniel F. Hayes, MD, believes having more consistent regulations by making things harder will actually make things easier to get new markers out.

Francisco J. Esteva, MD, PhD, said better systems need to be developed to integrate the clinical information with molecular data to ensure patients get the appropriate care.

John L. Fox, MD, MHA, is also looking forward to increased FDA oversight, although he added that it will still remain to be seen whether the medical community can ensure the tests are used appropriately so the right patients receive the right treatment.

Related Videos
H. John Beardsley, MBA, and Fauzea Hussain, MPH, sitting for a video interview
Adam Colborn, JD, associate vice president for congressional affairs, Academy of Managed Care Pharmacy (AMCP)
John Barkett, MBA
John Barkett, MBA
John Barkett, MBA
Tom Belmont
Dr Mingyang Song
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.